ITMCTR2000003368招募中4 期
A randomized, double-blind, placebo-controlled, multicenter clinical trial of tubeimoside injection for external use in the treatment of Verruca Plana
Shaanxi Provincial Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •1. Patients who meet the diagnostic criteria of Western medicine for verruca plana;
- •2. Patients aged 18-65 years;
- •3. Patients with skin lesions on trunk and limbs;
- •4. Patients who have not used the internal medicine related to this disease, such as vitamin A acid and interferon, have not used the external medicine related to this disease within 30 days before treatment;
- •5. For the patients without contraindications in this study;
- •6. Patients signing informed consent.
排除标准
- •1. The patients whose skin rash has obviously fused into pieces;
- •2. Pregnant and lactating women;
- •3. Patients with scar constitution and allergic constitution;
- •4. Patients with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, endocrine system, etc., in which alt, AST > 1.5 times of the upper limit of normal value, Cr, bun > 1.2 times of the normal value;
- •5. Patients with neurological and mental disorders who are unable to cooperate, and those who suspect or have a history of alcohol and drug abuse;
- •6. Patients with HIV infection, tumor and low immunity;
- •7. Patients with interruption during treatment;
- •8. Patients who participated in other clinical trials in the past month.
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195